Compare DDI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDI | LXRX |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.1M | 703.3M |
| IPO Year | 2020 | 2000 |
| Metric | DDI | LXRX |
|---|---|---|
| Price | $11.37 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $19.00 | $4.15 |
| AVG Volume (30 Days) | 106.5K | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $8.10 | $0.71 |
| 52 Week High | $12.35 | $2.53 |
| Indicator | DDI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 54.21 |
| Support Level | $11.25 | $1.50 |
| Resistance Level | $12.35 | $2.53 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 13.00 | 52.33 |
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States, while it also has its presence in Canada, Germany, United Kingdom, and International-Other. The games offered by the company are: Doubledown Casion, Doubledown Fortknox, and Doubledown Classic Slots.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.